A carregar...
Novel immunotherapies in lymphoid malignancies
The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid malignancies provided proof-of-principle for exploiting the immune system therapeutically. Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of T cells to target cance...
Na minha lista:
| Publicado no: | Nat Rev Clin Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4916838/ https://ncbi.nlm.nih.gov/pubmed/26525683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2015.187 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|